PD-1/PDL-1 Inhibitor Market

As per analysis of FMI, position of suppliers is being determined less by promotional muscle and more by an array of factors, including breadth of labeled indications, physician familiarity among frontline and perioperative protocols (the transition period prior to surgery), biomarker-linked treatment pathways and ability to maintain incorporation into hospital oncology formularies as immuno-oncology use shifts upwards in lines of care